UPDATE: Ladenburg Thalmann Raises PT to $16.50 on BG Medicine

Loading...
Loading...
Ladenburg Thalmann raises its price target on Buy-rated BG Medicine
BGMD
to $16.50 from $8.25 a share on strong top-line data for CardioSCORE. Ladenburg Thalmann says, "Based on the 2x improvement in predictive power for CardioSCORE over the current gold standard (Framingham Risk Score) and large size of the validation cohort, we believe CardioSCORE has established a firm footing for clinical utility as a screening tool. As such, we are adding the test to our revenue forecast with peak gross sales of $325M. The impact of CardioSCORE economics raises our base year EPS estimate (2017) from $0.71 to $1.42." BGMD closed at $8.27 a share on Monday.
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorPrice TargetReiterationIntraday UpdateAnalyst RatingsLadenburg Thalmann
We simplify the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...